A metabolic vulnerability of pancreatic ductal adenocarcinoma (PDAC) could be used to address this type of cancer that often resists treatments. Scientists at the University of Michigan have ...

Pancreatic cancer is a leading cause of cancer-related death, with a five-year survival rate of 13%. The high mortality is ...

The small-molecule PIKfyve inhibitor – called VRG50635 – has been administered to the first subject in the phase 1 trial involving healthy volunteers, according to the San Francisco-based ...

In a recent paper, published in Nature, researchers from the University of Michigan have discovered that simultaneously targeting PIKfyve and KRAS-MAPK can eliminate tumors in preclinical human ...

Takeda has bolstered its neuroscience pipeline by licensing drug candidates from California biotech AcuraStem targeting PIKfyve, which is gathering attention as a drug target in amyotrophic ...